Embryonic stem (ES) cells and their derivatives are an important resource for developing novel cellular therapies for disease. Controlling proliferation and lineage selection, however, are essential to circumvent the possibility of tumor formation and facilitate the safe translation of ES-based therapies to man. Expression of appropriate transcription factors is one approach to direct the differentiation of ES cells towards a specific lineage and stop proliferation. Neural differentiation can be initiated in ES cells by expression of Neurogenin1 (Ngn1). In this study we investigate the effects of controlled Ngn1 expression on mouse ES (mES) cell differentiation in vitro and following grafting into the rat spinal cord. In vitro, Ngn1 expression in mES cells leads to rapid and specific neural differentiation, and a concurrent decrease in proliferation. Similarly transplantation of Ngn1-expressing mES cells into the spinal cord lead to in situ differentiation and spinal precursor formation. These data demonstrate that Ngn1 expression in mES cells is sufficient promote neural differentiation and inhibit proliferation, thus establishing an approach to safely graft ES cells into the spinal cord.
Introduction
Embryonic stem (ES) cells have the potential to provide both cellular replacement and environmental enrichment, and are gaining interest as treatments for spinal cord injury and neurodegenerative disorders including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), stroke, and multiple sclerosis (Lunn et al., 2011; Payne et al., 2011; Sobani et al., 2010) . The overall safety of ES cell transplantation, however, poses a significant limitation on the potential use of these novel stem cell therapies (Drukker, 2006; Hentze et al., 2009) . Developing strategies to overcome adverse events including uncontrolled proliferation and incorrect lineage differentiation is important for the clinical translation of ES cell technology (Goldring et al., 2011) .
There are numerous therapeutic approaches that utilize neural progenitor cells (Lunn et al., 2011; Nishimoto et al., 2011; Yan et al., 2007) . These cells, however, have limited availability and restricted differentiation potential based on the cells' origin or specific culture conditions. ES cells, on the other hand, are widely available and may be stimulated to become neural progenitors. In addition, ES cells have a broader differentiation potential, and thus may provide a larger range of neuronal subtypes. In order to harness the potential therapeutic advantages of ES cells, unregulated proliferation and the development of tissue-inappropriate lineages needs to be controlled, and a safe approach to incorporate these cells into the central nervous system must be developed (Chung et al., 2006; Jung et al., 2007; Kiuru et al., 2009) .
One way to both minimize unregulated proliferation and control lineage specification is through expression of selective pro-neural regulatory factors during ES cell implantation. These factors drive the differentiation of developing ES cells towards desired lineages and in turn check excessive proliferation. Neurogenin 1 (Ngn1), a neurogenic basic helix loop helix (bHLH) transcription factor, is sufficient to drive neural differentiation and inhibit gliogenesis (Farah et al., 2000; Kim et al., 2008; Morrison, 2001; Reyes et al., 2008) . Ngn1 is expressed in the neural tube during development where it is a neural specification factor (Chesnutt et al., 2004; Nakada et al., 2004) ; therefore, overexpression of Ngn1 may initiate the differentiation of ES cells to promote subsequent patterning towards a spinal neural identity.
Ngn1-expressing mES cells under the control of a tet-on promoter allow the controllable induction of Ngn1 (designated N7 cells 
